share_log

Earnings Call Summary | Envista Holdings(NVST.US) Q1 2024 Earnings Conference

Earnings Call Summary | Envista Holdings(NVST.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Envista Holdings (NVST.US) 2024 年第一季度财报会议
moomoo AI ·  05/02 10:03  · 电话会议

The following is a summary of the Envista Holdings Corporation (NVST) Q1 2024 Earnings Call Transcript:

以下是Envista Holdings Corporation(NVST)2024年第一季度财报电话会议记录摘要:

Financial Performance:

财务业绩:

  • Envista reported Q1 sales of $623.6 million with a core sales growth of 0.4%.

  • The adjusted EBITDA margin was 14%, primarily affected by lower gross margins and investments.

  • Gross margin decreased by 70 points due to an unfavorable product mix and pricing.

  • Adjusted diluted EPS for Q1 was $0.26, down from $0.38 in the same period of the previous year.

  • The company generated $29.3 million as free cash flow, showing a significant improvement from the last year.

  • Planned structural cost improvements should amount to over $30 million, the full impact to be seen in 2025.

  • Q1 saw total investments worth $10 million, about 30% of which were one-time spending.

  • Envista报告称,第一季度销售额为6.236亿美元,核心销售额增长0.4%。

  • 调整后的息税折旧摊销前利润率为14%,主要受毛利率和投资下降的影响。

  • 由于不利的产品组合和定价,毛利率下降了70个百分点。

  • 第一季度调整后的摊薄每股收益为0.26美元,低于去年同期的0.38美元。

  • 该公司创造了2930万澳元的自由现金流,与去年相比有了显著改善。

  • 计划中的结构性成本改善应超过3000万美元,其全部影响将在2025年显现。

  • 第一季度的投资总额为1000万美元,其中约30%是一次性支出。

Business Progress:

业务进展:

  • Specialty Products and Technologies segment recorded a 0.8% sales increase.

  • Implant business showed a slump in Q1 but was partially offset by strong growth in China.

  • The orthodontic business, led by Spark clear aligners, grew in low-single digits.

  • Actions were taken to improve North American performance, including strengthening leadership and upgrading training capabilities.

  • Plans to accelerate implant production in North America aim to match market growth by the end of 2024.

  • Major investments, centered on training, partnerships, and Spark activities, aim to drive margin improvement and grow the implant business.

  • Aggressive plans are in place to bridge the growth underperformance in the North American implant market by year-end.

  • The company sees strong growth potential in the China market, as the price gap between premium and value products is narrowing.

  • 特种产品和技术板块的销售额增长了0.8%。

  • 植入业务在第一季度出现低迷,但部分被中国的强劲增长所抵消。

  • 以Spark透明对准器为首的正畸业务以低个位数增长。

  • 已采取行动改善北美的业绩,包括加强领导和提高培训能力。

  • 加快北美种植体生产的计划旨在到2024年底实现市场增长。

  • 主要投资以培训、合作伙伴关系和Spark活动为中心,旨在推动利润率提高和发展植入业务。

  • 已经制定了积极的计划,以在年底之前弥合北美植入物市场的增长表现不佳的情况。

  • 随着优质和超值产品之间价格差距的缩小,该公司认为中国市场具有强劲的增长潜力。

More details: Envista Holdings IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发